Advertisement
Advertisement
PRAX
Praxis Precision Medicines, Inc. Common Stock
360.76
USDSponsored
-9.40
-2.54%
Aug 07, 15:59 UTC -4
Closed
After-Market
366.00
+5.24
+1.45%
PRAX Earnings Reports
Positive Surprise Ratio
PRAX beat 11 of 24 last estimates.
46%
Next Report
Date of Next Report
Nov 03, 2026
Estimate for Q3 26 (Revenue/ EPS)
$62.77K
/-$4.03
Implied change from Q2 26 (Revenue/ EPS)
--
/+40.42%
Implied change from Q3 25 (Revenue/ EPS)
--
/+19.94%
Praxis Precision Medicines, Inc. Common Stock earnings per share and revenue
On Aug 06, 2026, PRAX reported earnings of -2.87 USD per share (EPS) for Q2 26, beating the estimate of -3.73 USD, resulting in a 23.14% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +15.95% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 11 analysts forecast an EPS of -4.03 USD, with revenue projected to reach 62.77 thousand USD, implying an increase of 40.42% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cytokinetics Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.67
Actual
-$1.50
Surprise
+10.35%
Celldex Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.07
Actual
-$0.94
Surprise
+12.79%
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Zymeworks Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.46
Actual
-$0.62
Surprise
-32.31%
Intellia Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.81
Actual
-$0.80
Surprise
+1.86%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Verastem, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.44
Actual
-$0.35
Surprise
+20.69%
ALX Oncology Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.13
Surprise
+11.08%
Arcturus Therapeutics Holdings Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.01
Actual
-$0.84
Surprise
+17.53%
FAQ
What were Praxis Precision Medicines, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Praxis Precision Medicines, Inc. Common Stock reported EPS of -$2.87, beating estimates by 23.14%, and revenue of $0.00, 0% as expectations.
How did the market react to Praxis Precision Medicines, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 15.95%, changed from $319.23 before the earnings release to $370.16 the day after.
When is Praxis Precision Medicines, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 03, 2026.
What are the forecasts for Praxis Precision Medicines, Inc. Common Stock's next earnings report?
Based on 11
analysts, Praxis Precision Medicines, Inc. Common Stock is expected to report EPS of -$4.03 and revenue of $62.77K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement